Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
2.860
+0.090 (3.25%)
At close: Apr 1, 2025, 4:00 PM
2.850
-0.010 (-0.35%)
After-hours: Apr 1, 2025, 7:28 PM EDT
Savara Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
601.96M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SVRA News
- 5 days ago - Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Business Wire
- 6 days ago - Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital - Business Wire
- 6 days ago - Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
- 15 days ago - Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 - Business Wire
- 26 days ago - Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
- 4 weeks ago - Savara Announces Participation in the Leerink Global Healthcare Conference - Business Wire
- 6 weeks ago - Savara Announces New Employment Inducement Grant - Business Wire
- 2 months ago - Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research - Business Wire